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Gender differences in coronary heart 
disease
Cardiovascular disease develops 7 to 10 years 
later in women than in men and is still the 
major cause of death in women. The risk of 
heart disease in women is often underestimat-
ed due to the misperception that females are 
‘protected’ against cardiovascular disease. The 
under-recognition of heart disease and differ-
ences in clinical presentation in women lead to 
less aggressive treatment strategies and a lower 
representation of women in clinical trials. Fur-
thermore, self-awareness in women and iden-
tification of their cardiovascular risk factors 
needs more attention, which should result in a 
better prevention of cardiovascular events. In 
this review we summarise the major issues that 
are important in the diagnosis and treatment of 
coronary heart disease in women. (Neth Heart 
J 2010;18:598-603.)
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Cardiovascular disease develops 7 to 10 years later in women than in men and is still the ma-
jor cause of death in women over the age of 65 
years. The risk of heart disease in women is often 
underestimated due to the misperception that fe-
males are ‘protected’ against cardiovascular disease. 
Recent data from the National Health and Nutri-
tion Examination Surveys (NHANES) have shown 
that over the past two decades the prevalence of 
myocardial infarctions has increased in midlife (35 
to 54 years) women, while declining in similarly 
aged men.1 In a report from the European Heart 
Survey on stable angina pectoris it was found that 
women are less likely to be referred for functional 
testing for ischaemia and that a lower rate of di-
agnostic angiograms and interventional procedures 
are performed compared with men.2 The under-
recognition of heart disease and differences in clini-
cal presentation in women lead to less aggressive 
treatment strategies and a lower representation of 
women in clinical trials. Furthermore, self aware-
ness in women and identification of their cardio-
vascular risk factors needs more attention which 
should result in a better prevention of cardiovascu-
lar events. In this review we summarise the major 
issues that are important in the diagnosis and treat-
ment of coronary heart disease (CHD) in women.
Epidemiology and role of menopause
It is assumed that exposure to endogenous oes-
trogens during the fertile period of life delays the 
manifestation of atherosclerotic disease in women. 
Before menopause the CHD event rate in women 
is low and predominantly attributed to smoking.3 
Women with an early menopause (<40 years) have 
a two-year lower life expectancy compared with 
women with a normal or late menopause.4 Data 
from the Framingham Heart Study suggest that 
a harmful cardiovascular risk profile may be more 
cause than consequence of age at menopause. 
In the Women’s Ischemia Syndrome Evaluation 
(WISE) study it was shown that young women with 
endogenous oestrogen deficiency have a more than 
sevenfold increase in coronary artery risk.5 Oestro-
gens have a regulating effect on several metabolic 
factors, such as lipids, inflammatory markers and 
the coagulant system. They also promote a direct 
vasodilatory effect through the α and β receptors 
in the vessel wall. Furthermore, signs of subclini-
cal atherosclerosis, as visualised by intima-media 
thickness measurements, can already be found in 
women before menopause, especially when sev-
eral CHD risk factors are present.6 Flow-mediated 
vaso reactivity by brachial artery measurements de-
clines with the time elapsed since menopause. Af-
ter menopause atherosclerotic plaque composition 
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changes into more vulnerable lesions with inflam-
matory factors involved. 
Gender differences in major CHD risk factors 
Menopause transition is associated with a worsen-
ing CHD risk profile.7  
 Women with clinically manifest CHD are in 
general older than men, with a higher expression 
of cardiovascular  risk factors.8,9 Although women 
and men share most classic risk factors, the signifi-
cance and the relative weighting of these factors are 
different. At younger ages (<50 years) smoking is 
more deleterious in women than in men, with a 
larger negative impact of the total number of ciga-
rettes smoked per day.3,10 Smoking increases the 
risk of a first acute myocardial infarction (AMI) 
relatively more in females than in men. In young 
premenopausal women smoking causes a downreg-
ulation of the oestrogen-dependent vasodilatation 
of the endothelial wall.11 Whether smoking reduces 
age at menopause remains a matter of debate. 
 Body weight may increase during the first years 
since menopause and body fat distribution changes 
from a gynoid to a more android pattern. Cen-
tral obesity with an increase in visceral fat occurs 
more frequently after menopause, with a higher 
presence of comorbid risk factors and components 
of the metabolic syndrome in women compared 
with ageing men.12 With the increasing incidence 
of obesity there is a parallel increase in the preva-
lence of type 2 diabetes. Women with diabetes are 
at greater risk for cardiovascular complications than 
their male counterparts. In a meta-analysis of 37 
prospective cohort studies, the risk of fatal CHD is 
50% higher in women with diabetes compared with 
male diabetics.13 The reason for this higher mor-
tality is multifactorial and related to a heavier risk 
factor burden, more involvement of inflammatory 
factors, smaller vessel size of the coronary arteries 
and an often less aggressive treatment of diabetes in 
women. 
 Systolic blood pressure rises more steeply in 
ageing women compared with men, and this 
may be related to the decline in oestrogen lev-
els in menopause transition.14-16 After menopause 
there is an upregulation of the renin-angiotensin 
system, with an increase in plasma-renin activ-
ity. Salt sensitivity and sympathetic activity are 
also increased in postmenopausal compared with 
premenopausal women. At older age (>75 years) 
isolated systolic hypertension is 14% more prev-
alent in women and an important cause of left 
ventricular hypertrophy, (diastolic) heart failure 
and strokes. Moderate or borderline hyperten-
sion (<140/90 mmHg) causes more endothelial 
dysfunction and cardiovascular complications in 
women than in men.17 Hypertension often starts 
in the menopausal transition period and can cause 
a variety of complaints, such as chest pain, pal-
pitations, headaches and even sensations of hot 
flashes.18 These complaints are often attributed to 
menopause but are less prevalent when elevated 
blood pressure is adequately treated.19 It is con-
troversial whether women who have relatively 
more vasomotor symptoms during menopause 
transition are at greater risk for CHD.20
 At younger age, the relative risk of hypercholes-
terolaemia is lower in women compared with men. 
During menopause, total cholesterol and low-den-
sity lipoprotein (LDL) levels rise by 10 and 14% 
respectively and lipoprotein (a) increases 4 to 8%, 
whereas high-density lipoprotein (HDL) choles-
terol levels remain unchanged.7,21 It may therefore 
be important to (re)evaluate the lipid profile after 
menopause when borderline premenopausal values 
were found. Above 65 years of age mean LDL cho-
lesterol is higher in women compared with men. 
At all ages HDL-cholesterol levels are 0.26 to 0.36 
mmol/l higher in women but from the Framing-
ham study it is known that a low HDL cholesterol 
implicates a higher CHD risk in women than in 
men.22 Although women have often been under-
represented in many statin trials in the past, there 
is currently no doubt that in secondary prevention 
LDL reduction in women leads to an equally lower 
CHD mortality as in men.23 On the other hand, 
in primary prevention the role of statin therapy in 
women is still controversial. Caution is needed, 
however, as women have a lower absolute risk in 
the age groups that have been studied thus far. A 
recent large Japanese study showed clear benefits 
of primary prevention with statins in women with 
moderately elevated cholesterol levels above the 
age of 55 years.24 The age difference in the occur-
rence of CHD events among men and women was 
accounted for in the JUPITER trial, where compa-
rable benefits of primary prevention with a statin 
were found in healthy men ≥50 years and in wom-
en ≥60 years with normal LDL levels but elevated 
hs-CRP levels.25
Female-specific risk factors
Although studies have shown that hormonal dys-
function in premenopausal women is associated 
with an increased risk of atherosclerosis and CHD 
events, it is still unclear whether the polycystic 
 ovary syndrome (PCOS) is an independent risk fac-
tor for atherosclerosis.5,26 PCOS occurs in 8 to 10% 
of women and is an important cause of infertility. 
Women with this syndrome are at increased risk 
for development of the metabolic syndrome and 
type 2 diabetes mellitus. The difficulty in studying 
cardiovascular events in women with PCOS is due 
to the low prevalence of these events in premeno-
pausal women. A greater clustering of CHD risk 
factors and an adverse CHD event rate was found 
in postmenopausal participants with PCOS within 
the WISE study population.27
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Women with a history of hypertensive diseases in 
pregnancy are at increased risk for hypertension 
and premature cardiovascular disease later in life. 
Especially in women after preeclampsia, defined 
as hypertension (≥140/90 mmHg) and protein-
uria (≥0.3 g/24 h) after 20 weeks of gestation, 
the risk of future CHD is twice as high compared 
with women who were normotensive during preg-
nancy.28 Women with a placental syndrome in com-
bination with poor foetal growth or intrauterine 
death are considered to be at greatest risk.29 Hyper-
tensive disorders are thought to be associated with 
an abnormal placentation leading to aberrant auto-
nomic control and inappropriate release of vasoac-
tive substances causing endothelial dysfunction in 
the maternal and foetal circulation. In women with 
gestational diabetes the relative risk to develop type 
2 diabetes is even 7 to 12 times higher compared 
with women with normoglycaemic pregnancies.30 
The characteristics of pregnancy-related disorders 
provide a unique opportunity for a better cardio-
vascular risk assessment and prevention, but have 
not yet been incorporated in the latest guidelines 
for CHD prevention in women.31
Clinical presentation and noninvasive testing 
for angina pectoris
The clinical presentation of coronary artery disease 
and the interpretation of noninvasive diagnostic 
testing is less reliable in women compared with 
men, especially in the age group below 55 years 
when the prevalence of coronary artery disease is 
still relatively low.32-34 Chest pain syndromes are 
more common in women than in men and are less 
related to the presence of atherosclerosis in the 
large epicardial coronary arteries.8,35-37 In addition, 
many causes of noncardiac chest pain can mimic the 
discomfort that is associated with myocardial isch-
aemia. Women who are diagnosed with noncardiac 
chest pain have a twofold increased risk to develop 
a CHD event in the next five to seven years and 
have a four times higher risk for re-hospitalisations 
and recurrent angiograms in the next 180 days.38,39 
This implicates that traditional diagnostic methods 
are not optimal for women and that they should be 
treated more aggressively for their risk factors.
 There are no gender-specific criteria for the 
interpretation of ECGs, although women have a 
higher heart rate at rest with a longer QT interval. 
Nonspecific ECG changes at rest, a lower exercise 
capacity and a smaller vessel size contribute to the 
lower sensitivity and specificity of noninvasive test-
ing in women.33 At younger ages, endogenous oes-
trogen levels can induce ECG changes mimicking 
ischaemia. Female-specific normograms have been 
developed for treadmill exercise testing. A low ex-
ercise capacity in symptomatic as well as in asymp-
tomatic women is a strong predictor of five-year 
mortality. Diagnostic accuracy of exercise testing in 
women can be further improved by assessment of 
the angina history, oestrogen status and the pres-
ence of major CHD risk factors.40
 Stress echocardiography with exercise or dobuta-
mine can be an important test to evaluate wall mo-
tion abnormalities and its clinical value is not dif-
ferent between the two genders. The accuracy of 
myocardial perfusion imaging scans used to be less 
in women in the past due to smaller vessel size and 
breast attenuation, but with more advanced SPECT 
imaging techniques performed with Technetium 
sestamibi the predictive value of the scans has im-
proved dramatically.33 It remains important, how-
ever, to include signs of chest pain, electrocardio-
graphic abnormalities and a low functional capacity 
in the interpretation of the scans. Microvascular dys-
function and diffuse coronary atherosclerosis with-
out obstructive lesions is more prevalent in women 
than in men and can be better visualised with posi-
tron emission tomography (PET) and cardiovascular 
magnetic resonance (CMR) techniques.37,41 The 
relative low availability of these imaging modalities 
may be an important factor in the under-recognition 
of these syndromes in women. Calcium scoring with 
EBTC or multi-slice CT is a very useful modality 
to rule out the presence of obstructive CHD, but 
the (cumulative) radiation exposure makes this tech-
nique less suitable in premenopausal women and 
for follow-up purposes. In women >50 years of age 
who are at intermediate risk for CHD the absence 
of coronary calcium has a very high (99%) negative 
predictive value for obstructive coronary athero-
sclerosis. In all age groups calcium scores are lower 
in women than in men.42 Also, the use of coronary 
computed tomographic angiography (CCTA) at the 
emergency department is promising as a highly sen-
sitive diagnostic tool in the early triage of women 
<65 years who present with symptoms of acute chest 
pain, but this technique has comparable limitations 
due to radiation exposure.37
Acute coronary syndromes in women
Many analyses of sex-based differences following 
acute coronary syndromes (ACS) have revealed 
conflicting results. At presentation in STEMI, 
both men and women have comparable symptoms 
of chest pain, but women tend to have more con-
comitant vaso-vegetative symptoms that can mask 
the chest pain, with less extensive ST-T elevations at 
admission especially at younger ages.8,43,44 In women 
below 55 years of age unstable angina pectoris and 
non-STEMI are often misdiagnosed at the emer-
gency department.45 Women with ACS are gener-
ally older with more clustering of risk factors that 
may contribute to their higher risk of mortality.8,9,46 
Gender bias in treatment and gender disparities in 
vascular flow and structure may further add to this 
increased mortality. An interesting observation is 
that women with ACS have less extensive obstruc-
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tive and more diffuse coronary artery disease com-
pared with men, but the event rate in nonobstruc-
tive coronary artery disease seems to be higher in 
women.8,37,47 In a recent large meta-analysis of 11 
randomised ACS trials it was shown that sex-based 
differences in 30-day mortality among patients with 
various manifestations of ACS are largely explained 
by clinical differences at presentation and the sever-
ity of angiographically documented disease.48 Other 
aspects that may account for differences in outcomes 
between women and men are related to vascular bi-
ological factors such as a smaller atheroma burden 
and slower progression in women, a smaller vessel 
size, less collateral flow, lower coronary flow reserve, 
more vascular stiffness, differences in remodelling, 
and functional differences of smooth muscle cells in 
the vessel wall.35,37,47 While in STEMI both genders 
have equal benefit of early percutaneous coronary 
interventions (PCI), there is abundant evidence that 
in non-STEMI the therapeutic strategies should 
be different between men and women.47,49 In the 
FRISC II and RITA 3 trials, early invasive strategy 
of patients with unstable angina or non-STEMI 
ACS was proven to reduce mortality in men, but not 
in women. A meta-analysis of eight combined non-
STEMI trials has confirmed that an early conserva-
tive strategy in low-risk (biomarker-negative) wom-
en is better than an early invasive strategy, which is 
in line with the already updated ACC/AHA guide-
lines on non-STEMI in 2007.50 
 Mortality after coronary artery bypass surgery 
(CABG) is higher in women compared with men 
and this difference is more pronounced in the 
younger age groups, after adjustment for risk fac-
tors.51 Many factors influence this gender gap, such 
as comorbid conditions at older age, smaller vessel 
size, more urgent procedures in women and the 
presence of hypertensive heart disease. Further-
more, after PCI women have significantly more 
bleeding complications, especially when glyco-
protein IIb/IIIa inhibitors are used.52 In a meta-
analysis of various large ACS trials, no differences 
were found in the efficacy and safety of clopidogrel 
between men and women.53
Chest pain with ‘normal’ coronary angiograms
At younger ages women more often have ACS 
with angiographically ‘normal’ coronary arteries 
than men.8,47 The underlying mechanisms of this 
so-called coronary microvascular dysfunction are 
diverse and may be related to endothelial reactiv-
ity, low endogenous oestrogen levels, coagulation 
disorders, abnormal inflammatory reactions and 
its manifestation can have a substantial variability 
among individuals.37 Abnormal cardiac nociception 
can further attribute to persistent chest pain due to 
an increased coronary pain perception in women.54 
When symptoms of microvascular dysfunction re-
sult in objective signs of ischaemia it is proposed 
to call this syndrome microvascular angina pectoris. 
The relationship between microvascular dysfunc-
tion and epicardial atherosclerosis is not yet fully 
understood. The prognosis of this syndrome is less 
beneficial than initially considered and often leads 
to recurrent hospitalisations and repeated coronary 
angiograms.39,55 The prognosis is worse in women 
with various risk factors and these should be treat-
ed aggressively to prevent future CHD events.
Conclusion
Cardiovascular disease is the major cause of death in 
women and is still under-recognised and undertreat-
ed. A greater awareness of the differences in presen-
tation of angina pectoris and ACS between men and 
women, with gender-based interpretation of diag-
nostic tests, is mandatory for health care profession-
als to improve therapeutic strategies and outcomes 
in women. Cardiology guidelines should be more 
focused on sex-related differences when appropri-
ate. Further, women themselves need to be more 
aware of their own risk factors and clinical signs of 
CHD. Many biological differences in atherosclerosis 
between men and women are not yet clarified and 
will need further research in the future. ■
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CVOI E-learning formula! 
This is the CVOI e-learning article. The author has prepared 10 questions which are 
available through the website of our Cardiovascular Educational Institute (CVOI). Please 
 follow the instructions below.
Website:  www.cvoi.nl
Press button: “toetsvragen”
Login:   NHJtoets12
Password:  011210
After finishing the questions you will be asked to fill in your name, hospital and e-mail address; then press the button “verzenden”.  
When 6 out of the 10 questions are answered correctly, you acquire 1 accreditation point granted by the Quality Commit-
tee of our Netherlands Society of Cardiology (NVVC). The acquired accreditation point will be credited in your personal file in 
the GAIA system.  You will also receive an enclosure by e-mail with all the correct answers.
Please note that the questions of every article are available on the CVOI website for just one month until the publication of 
the next e-learning article (on the 10th of each month).
Over a period of one year 10 e-learning articles will appear in 10 subsequent NHJ editions. In every NHJ edition (except 
the July/ August edition) a special e-learning article will be published recognisable by a special icon. On an annual basis 
you can collect 10 accreditation points. The accreditation points are credited in the GAIA system by the CVOI.
If you need additional information, please contact the CVOI by mail: cvoi@cvoi.org or by phone: 030-2345001.
We invite all readers of the NHJ to actively take part in this new, instructive and stimulating way of e-learning.
E.E. van der Wall
Chief Editor
Netherlands Heart Journal
e-learning
